Wednesday, July 5th
  • About Us
  • Copyright
  • Disclaimer
  • Privacy Policy
  • Terms&Conditions
  • Contact Us
    • Advertisement
  • Site Map
Biosimilar News
  • Twitter
  • RSS
  • News/Headlines
  • Events
    • Upcoming Events
    • Past Events
  • Guidelines
  • Policies
  • Research/Analysis
USEFUL TIP: In order not to miss any updates, follow us on Twitter or sign up for our Newsletter..

Follow Us

  • Subscribe by RSS Subscribe by RSS
  • Contact us via E-Mail
  • Follow us on Twitter
  • Follow us on LinkedIn
 

Sign up for our newsletter

All-time Popular Posts

  • A biobetter trastuzumab is on the way A biobetter trastuzumab is on the way
  • EGA president calls on Member States to boost market access for biosimilars in the EU EGA president calls on Member States to boost market access for biosimilars in the EU
  • 3rd Forum on Biosimilars 3rd Forum on Biosimilars
  • Pfizer starts biosimilar rituximab Phase I/II trial Pfizer starts biosimilar rituximab Phase I/II trial
  • Indian Biosimilars Market Indian Biosimilars Market
  • World’s first biosimilar antibody* is approved in Korea World’s first biosimilar antibody* is approved in Korea
  • A biosimilar manufacturer: Celltrion A biosimilar manufacturer: Celltrion
  • 2 patents down, 1 to expire: Herceptin biosimilar coming to EU 2 patents down, 1 to expire: Herceptin biosimilar coming to EU

Archives

Twitter Updates

Archive for March, 2013

March 28, 2013 9:30 AM

Generics and Biosimilars in Central and Eastern Europe

March 27, 2013 9:03 AM

Improving Patient Recruitment in Biosimilar Trials

March 27, 2013 8:42 AM

Biosimilar monoclonal antibodies: In vitro analytical testing and characterization of quality attributes and potency

March 27, 2013 8:28 AM

Drug Development Boot Camp 2013

© Copyright 2017 — Biosimilar News. All Rights Reserved Powered by Wordpress